Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson
New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…
Different packaging, typos expose fake Mounjaro racket
Gurugram: Colour dissimilarity to typographical errors… conspicuous differences in the packaging of counterfeit Mounjaro injections led the Drugs Control Office to crack down on the illicit sale and production of…
Sale of fake obesity drugs driven by high prices, weight-loss desire prompts health concern
Ozempic and Mounjaro are brand names of the ‘GLP-1 receptor agonist’ class of medicines, which help one manage diabetes and obesity by targeting appetite and enhancing satiety, resulting in a…
Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma
New Delhi: Improving access to new age medicines for obesity and diabetes over the next few years would be a key enabler for the growth of the domestic pharmaceutical industry,…
Lilly launches Mounjaro KwikPen in India
Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…
Popular diabetes drug, Mounjaro, launched in India
Mounjaro (tirzepatide): A breakthrough drug for the treatment of Type 2 diabetes and obesity, has been released in India. The drug has been approved by the Central Drugs Standard Control Organization…
